Our results derived from experiments using pharmacological inhibition indicate that both of these signaling pathways can drive both the PM-triggered expression of cFLIP(L) as well as the DF-induced synthesis of cFLIP(S) in luminal breast cancer cells. The gene discussed is CFLAR; the disease is breast carcinoma.